Denosumab Use in Chronic Renal Failure

Sezer SAĞLAM

Department of Medical Oncology, T.C. Demiroğlu Bilim University Faculty of Medicine, Istanbul-Turkey

Introduction

Chronic kidney failure (CRF) is an organ failure caused by the complete loss of kidney function. The kidneys are the last organ where vitamin D is activated. Therefore, a chronic vitamin D3 (calcitriol) deficiency that cannot be activated can cause a variety of problems such as calcitriol deficiency, biochemical hyperparathyroidism, relatively low parathyroid hormone level, increased alkaline phosphatase (hyperphosphatemia), increased fibroblast growth factor-23, high bone turnover disease, adynamic bone disease, vascular calcification, hyper-hypophosphatemia, and hyper-hypocalcemia.[1]

There are very few publications on its use in chronic renal failure. Most of earlier studies are case presentations. Denosumab’s official website suggests that when creatinine clearance is below 30%, the risk of hypocalcemia is high and it should be supplemented with calcium and vitamin D.[2]

In the multiple myeloma randomized study in which the most renal problems were experienced, we do not have information because the group with creatinine clearance below 30% was not included because zoledronic acid was a control group.[3] The half-life of denosumab does not increase for patients with creatinine clearance below 30% in CRF.

In a study, when the effects of single dose denosumab injection in patients with impaired renal function were examined, 15% cases with hypocalcemia, 15% with extremity pain and 11% with nausea were reported without calcium and vitamin D supplements.[4]

Again, in a case report, CRF was found to correct osteoporosis with 60 mg of denosumab, calcium and vitamin D every six months.[5]

Denosumab can be used in patients with CRF by closely monitoring the calcium level and giving active vitamin D (calcitriol).

References